For a while, Elizabeth Holmes was the most celebrated young entrepreneur in America — a Stanford dropout in a black turtleneck who had, the story went, invented a machine that could run hundreds of medical tests from a single painless drop of blood from a finger-prick. She was the youngest self-made female billionaire in the world, her company valued at nine billion dollars, her board a wall of American statesmen, her face on every magazine cover. The only problem, as the journalist John Carreyrou put it in the title of the book that helped destroy her, was that the technology didn’t work. None of it. The blood-testing revolution she had sold to investors, to retail pharmacies, and — most damningly — to real patients making real decisions about their health, was a fiction wrapped around someone else’s machines.
Theranos is the story of what happens when Silicon Valley’s “fake it till you make it” ethos collides with the one industry where the gap between the pitch and the product is measured not in disappointed shareholders but in human lives.
The girl who wanted to be a billionaire
Elizabeth Holmes was born in 1984 and raised partly on the memory of vanished family greatness — she was descended from the founder of Fleischmann’s Yeast, a Gilded Age fortune long since gone. By her own account she wanted, from childhood, not merely to be rich but to be historic, to build something that mattered, to be a name. She went to Stanford to study chemical engineering, and there persuaded a celebrated professor, Channing Robertson, to back her idea — the first of many borrowed credibilities that would, again and again, substitute for a working product. In 2003, at nineteen, she dropped out and used her tuition money as seed funding for the company she would eventually call Theranos, a fusion of “therapy” and “diagnosis.”
The vision she sold was genuinely good, which is exactly why it worked. She spoke of a fear of needles and of a world in which a single finger-prick could run a full battery of tests, catching disease early, putting the lab in every home and drugstore, democratizing health itself. It was Apple for blood — beautiful, humane, intuitive — and it made everyone who heard it want it to be true.
What made Holmes singular was how deliberately she built the persona to carry the vision. She idolized Steve Jobs and copied him down to the black turtleneck. She cultivated a startlingly deep baritone voice — an affectation, by most accounts, that she could drop into her natural higher register when she forgot herself. She understood, perhaps before her product existed at all, that in Silicon Valley the founder is the product, that capital flows to a compelling story embodied in a mythologizable figure. She built the figure first and waited for the blood test to catch up.
Somewhere along the way she met Ramesh Balwani — known as Sunny — a businessman nineteen years her senior whom she’d first encountered as a teenager. He became her secret romantic partner and the company’s president and enforcer, and together they ran Theranos in a culture that former employees described as one of secrecy and fear.
The machine that didn’t work
The entire empire rested on a single claim: that Theranos’s proprietary analyzer — eventually called the Edison — could run a comprehensive range of tests from a tiny finger-prick sample. The reality was that the Edison could perform only a small handful of tests, and even those it performed unreliably, producing results that were frequently wrong.
So how did Theranos run blood tests on actual patients in actual drugstores? It cheated. The company secretly ran the vast majority of its patient samples on ordinary, commercially available machines — the same Siemens-class analyzers any commercial lab already owned, the very technology Theranos claimed to be rendering obsolete — sometimes diluting the tiny finger-prick samples to make them usable on equipment never designed for such small volumes, which degraded the accuracy even further. The revolutionary device was, in large part, a prop.
Because the product didn’t work, Theranos became, in effect, a theater company. It staged fake demonstrations for investors, presenting a sample as though the Edison were processing it when the real testing happened elsewhere. When Vice President Joe Biden toured the facility, Holmes and Balwani built him a fake laboratory to conceal the real operating conditions. They claimed the technology had been deployed by the U.S. military on the battlefield in Afghanistan and on medevac helicopters — it never had. They projected more than a hundred million dollars in revenue for 2014; the company actually generated a little over a hundred thousand. They were off by a factor of a thousand.
What Holmes could not offer — a working product, real revenue — she compensated for with the most spectacular board of directors in American business, a wall of statesmen whose very names said trust us. The former Secretary of State George Shultz joined and personally recruited most of the others: Henry Kissinger, the future Defense Secretary James Mattis, former senators, a retired admiral, the former head of Wells Fargo. The celebrated litigator David Boies served on the board too. It was a board with almost no medical expertise and immense political gravity, and its credibility became the collateral for the fraud.
On the strength of the story, the persona, and the board, Theranos raised more than seven hundred million dollars and reached a peak valuation of around nine billion. The investors were a galaxy of marquee names — the Walton family of Walmart, Rupert Murdoch, Betsy DeVos, the Cox family, Larry Ellison — each of whom lost tens or hundreds of millions. In 2014, Forbes crowned Holmes the world’s youngest self-made female billionaire, with a paper fortune of four and a half billion dollars, a number the magazine would revise to essentially zero two years later.
And then, in 2013, Theranos struck a deal with the pharmacy chain Walgreens to put blood-collection “wellness centers” inside its stores. The unreliable testing was now in front of real patients, making real decisions about their health, on the basis of results from a machine that the company itself would eventually be forced to void — withdrawing two years of its own test results.
The people who knew
Long before the journalists, the person who understood the truth best was inside the building. Ian Gibbons was a distinguished British biochemist, named on some two hundred patents over a thirty-year career, whom Holmes hired in 2005 as the company’s first serious scientist. And Gibbons knew, early and unequivocally. As far back as 2006 he was telling Holmes the technology was not accurate and not fit for use on the public. To his wife he was blunter: “Nothing at Theranos is working.”
His fate is the tragic heart of the story. Gibbons became ensnared in the company’s litigation, and in May 2013, the night before he was due to give a deposition, he took an overdose. He died days later, at sixty-seven. The company that had pushed him to that edge reportedly responded not with condolences to his widow but with a letter demanding the return of confidential property.
The next truth-tellers were young employees who refused to take part in the deception. One was Tyler Shultz — who happened to be the grandson of board member George Shultz. He discovered the testing irregularities, raised them internally, was rebuffed, and became a key source for the press, at devastating personal cost: it pitted him against his own revered grandfather and subjected him to the company’s lawyers. His colleague Erika Cheung blew the whistle alongside him, and her complaint helped trigger the regulatory inspection that would eventually shut the labs down.
The decisive outside force was John Carreyrou, an investigative reporter at the Wall Street Journal, who in 2015 ran a secret, months-long investigation into whether Theranos could really do what it claimed. In October of that year, the Journal published his bombshell: the Edison gave inaccurate results, and the company was secretly using ordinary commercial machines for most of its testing.
Theranos did not respond to the scrutiny with transparency. It responded with legal terror, orchestrated through its board member, the superstar attorney David Boies — threatening the newspaper, and hounding the young whistleblowers with surveillance and ruinous legal pressure. In one extraordinary move, Holmes went over the newspaper’s head directly to its owner, Rupert Murdoch, who by then was Theranos’s single biggest investor with a hundred and twenty-five million dollars on the line, and asked him to kill the story. Murdoch — with every financial incentive to spike the piece that would vaporize his investment — refused, saying he trusted his editors to handle it fairly. It is a rare, gleaming moment of institutional integrity in the whole affair.
Once the dam broke, the collapse was swift. Regulators found the lab a danger to patients and banned Holmes from operating one. Theranos voided two years of test results, closed its labs and wellness centers, and saw its valuation evaporate. Forbes reset Holmes’s net worth to zero. The lawsuits piled up, and the company was formally dissolved in 2018.
The reckoning
That same year, the Securities and Exchange Commission charged Holmes and Balwani with raising more than seven hundred million dollars through an elaborate, years-long fraud. Holmes settled the civil charges — paying a penalty, surrendering control of the company, accepting a ban from leading a public company — without admitting wrongdoing. But that was only the civil case. A criminal indictment followed.
Holmes’s trial ran through the second half of 2021 and into the new year, and on the 3rd of January, 2022, the jury delivered a verdict whose split is the most revealing fact in the entire story. They found her guilty on four counts of defrauding investors. And they found her not guilty on the counts of defrauding patients. She was convicted of deceiving the billionaires. She was acquitted, to the criminal standard, of harming the sick.
At trial Holmes took the stand and raised a defense against Balwani, testifying that during their secret relationship he had controlled, berated, and at times sexually abused her. But she also testified — and this is the part the sympathetic retellings tend to leave out — that he had not forced her to make the false statements that were the actual substance of the case. Balwani categorically denied the abuse, calling the allegations false and inflammatory. The jury’s verdict tracked the narrow truth of her own testimony: the coercion claim, whatever its merits, did not erase her authorship of the lies.
In November 2022, a judge sentenced Holmes to eleven and a quarter years in prison and ordered her, jointly with Balwani, to pay four hundred and fifty-two million dollars in restitution. She reported to a minimum-security federal prison in Texas in May 2023. Sunny Balwani, tried separately, fared worse — convicted on all twelve counts, including the patient-fraud charges Holmes was acquitted of, and given a slightly longer sentence. The enforcer was judged more harshly than the face.
The deepest question the story leaves behind is the one the law could not answer: was Elizabeth Holmes a deliberate fraudster, or a true believer who convinced herself that the machine would eventually work and that she was merely faking it until she made it, in the great Silicon Valley tradition? The record convicts her of fraud. It is silent on her soul. What is certain is that she understood, better than almost anyone, that in the modern world a sufficiently compelling story, told by a sufficiently compelling figure, can raise hundreds of millions of dollars and put a broken machine into pharmacies across the country — and that the people who paid the price were not, in the end, the billionaires on her board, but the patients who trusted a drop of their own blood to a lie.
Power and Pelf 